Knight Terapeutics and Eurofarma eye Biotoscana -Brazil Journal blog

Canada's Knight Terapeutics and Brazilian pharmaceuticals company Eurofarma are interested in acquiring control of Biotoscana Investments SA, financial blog Brazil Journal reported on Monday, citing unnamed sources.

SAO PAULO, Oct 7 (Reuters) - Canada's Knight Terapeutics GUD.TO and Brazilian pharmaceuticals company Eurofarma are interested in acquiring control of Biotoscana Investments SA GBIO33.SA, financial blog Brazil Journal reported on Monday, citing unnamed sources.

Biotoscana's largest shareholders, private equity firm Advent International and specialist investment firm EW Healthcare Partners, are in talks with the groups, Brazil Journal said.

Shares in Biotoscana rose 15% in early trade to 9.25 reais ($2.28) after the report.

Advent, EW Healthcare, Eurofarma, Knight Terapeutics and Biotoscana did not reply immediately to requests for comment.

($1 = 4.0648 reais)

(Reporting by Tatiana Bautzer Editing by David Goodman)

((tatiana.bautzer@tr.com; Tel: +55-11-5644-7756; Mob: +55-119-4210-4173; Reuters Messaging: tatiana.bautzer.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More